INNOVIVA, INC. Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share
INNOVIVA, INC. (INVA) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share of $0.00 per share for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-28.
Discontinued › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare · last filed 2017-02-28
- INNOVIVA, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2016 was $0.00.
- INNOVIVA, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2015 was $0.00.
- INNOVIVA, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2014 was -$0.84.
| Period end | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 12 month |
|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-02-28 |
| 2015-12-31 | $0.00 10-K · filed 2017-02-28 |
| 2014-12-31 | -$0.84 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |